CLDI News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CL

Volume

33.20K

Next Earnings

November 12th

Loading chart

CL

CLDICalidi Biotherapeutics, Inc.

CLDI

Pay with—

Available Balance0.00

CL

Mkt Cap

$2.2M

Volume

33.20K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity DeficiencyCalidi Biotherapeutics received a notice from NYSE American on September 21, 2026, indicating non-compliance with continued listing standards due to stockholders' equity deficiency of less than $4.0 million. The company has until October 21, 2026, to submit a compliance plan and must regain compliance by March 21, 2028, or face delisting proceedings. The company's stock will trade with a '.BC' designation indicating below-compliance status, though trading continues unaffected.GlobeNewswire Inc. · Sep 25, 2026

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026Calidi Biotherapeutics announced a 1-for-16 reverse stock split effective July 31, 2026, approved by stockholders on June 12, 2026. The company aims to optimize market dynamics and broaden investor appeal. Every 16 pre-split shares will consolidate into one share, with fractional shares rounded up to the nearest whole share.GlobeNewswire Inc. · Jul 20, 2026

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human StudyCalidi Biotherapeutics announced it received positive pre-IND feedback from the FDA for its lead candidate CLD-401, an oncolytic virus with IL-15 superagonist delivery. The company plans to submit an IND application by end of 2026 and initiate first-in-human clinical trials in early 2027. The FDA alignment on CMC, non-clinical programs, and clinical study design represents a significant regulatory milestone for the company's RedTail platform.GlobeNewswire Inc. · Jun 16, 2026

Calidi Biotherapeutics Provides Required NYSE American DisclosureCalidi Biotherapeutics disclosed that its 2025 annual financial statements include an audit report with a going concern explanatory paragraph, indicating substantial doubt about the company's ability to continue operations. The company is advancing its RedTail platform for genetic medicine delivery, with lead candidate CLD-401 in IND-enabling studies for cancer treatment.GlobeNewswire Inc. · May 22, 2026

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment OptionCalidi Biotherapeutics completed a $6.0 million underwritten public offering, selling 12.1 million shares of common stock along with Series J, K, and L warrants. Ladenburg Thalmann & Co. Inc. served as sole book-running manager. The warrants have exercise prices of $0.50 per share with varying expiration terms and include reset provisions.GlobeNewswire Inc. · Mar 10, 2026

Calidi Biotherapeutics Announces Proposed Public OfferingCalidi Biotherapeutics announced an underwritten public offering of units consisting of common stock and warrants, with Ladenburg Thalmann & Co. Inc. as sole book-running manager. The company intends to use net proceeds for working capital and general corporate purposes. The offering is subject to market conditions and there is no assurance as to completion timing or final terms.GlobeNewswire Inc. · Mar 5, 2026

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO ConferenceCalidi Biotherapeutics presented preclinical data on its RedTail virotherapy platform, which enables systemic delivery of bispecific T-cell engagers (BiTEs) and IL-15 superagonist directly to solid tumors. The approach aims to overcome BiTE limitations in solid tumors by remodeling the tumor microenvironment and activating T-cells. The company is conducting IND-enabling studies for CLD-401 and plans to submit an IND application by end of 2026.GlobeNewswire Inc. · Feb 20, 2026

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO ConferenceCalidi Biotherapeutics announced it will present data on its RedTail platform, a systemically delivered virotherapy designed to deliver BiTEs and IL-15 superagonist to solid tumors. The company is conducting IND-enabling studies for CLD-401, its lead candidate, with plans to submit an IND application by end of 2026. RedTail addresses the limitation of BiTEs in solid tumors by remodeling the tumor microenvironment to enable T-cell activation.GlobeNewswire Inc. · Feb 12, 2026

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025Calidi Biotherapeutics is hosting an investor webinar to discuss its RedTail platform, an engineered viral therapy designed to deliver genetic medicines to tumor sites. The company aims to advance its technology towards IND filing by end of 2026, targeting oncology markets projected to exceed $560 billion by 2033.GlobeNewswire Inc. · Nov 17, 2025

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment OptionCalidi Biotherapeutics completed a public offering, raising $6.9 million by selling common stock units and pre-funded warrant units, with Ladenburg Thalmann & Co. Inc. acting as sole book-running manager.GlobeNewswire Inc. · Aug 21, 2025

to start trading

CL

CLDICalidi Biotherapeutics, Inc.

CLDI

Pay with—

Available Balance0.00

Your PositionYou don't own any CLDI yet.

Related Tickers

Earnings